Prospective, Double-Blind, Randomized, Placebo-Controlled Dose Finding Study of the Efficacy and Safety of 2 Target Doses of Org 34517 Used as Adjunctive Therapy in Subjects With Psychotic Major Depression (Major Depressive Episode, Severe, With Psychotic Features).

Trial Profile

Prospective, Double-Blind, Randomized, Placebo-Controlled Dose Finding Study of the Efficacy and Safety of 2 Target Doses of Org 34517 Used as Adjunctive Therapy in Subjects With Psychotic Major Depression (Major Depressive Episode, Severe, With Psychotic Features).

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2014

At a glance

  • Drugs ORG 34517 (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms Hermes
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 30 Sep 2013 Added Lead centre Merck as reported by ClinicalTrials.gov record (NCT00212797).
    • 30 Sep 2013 Added Lead centre Merck as reported by ClinicalTrials.gov record (NCT00212797).
    • 06 Oct 2009 Actual end date changed from (1 Nov 2005) to (1 Jul 2006) as reported by ClinicalTrials.gov. record (NCT00212797).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top